Preliminary observation on the efficacy of tumor-treating fields in the treatment of glioblastoma
Objective To investigate the clinical efficacy and adverse event(AE)of tumor-treating fields(TTFields)therapy in the treatment of glioblastoma(GBM).Methods A retrospective analysis was conducted on the clinical data of 12 patients with GBM treated at the Department of Neurosurgery of Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,from September 2019 to December 2023.Among the 8 newly-diagnosed patients,treatment involved radiotherapy combined with concomitant temozolomide(TMZ)at 2 to 6 weeks after tumor resection,followed by adjuvant TMZ and TTFields.For the 4 recurrent GBM patients,TTFields therapy was applied starting 2 to 6 weeks after redo surgery either as the sole treatment(1 patient)or alongside bevacizumab(3 patients).Regular follow-up was conducted every 2 to4 months,measuring overall survival(OS),progression-free survival(PFS),and AEs.The severity of AEs was evaluated using the Common Terminology Criteria for Adverse Events(CTCAE).Results TTFields were administered for a median daily duration of 23.0 hours(8.0-23.5 hours),with a median total usage duration of 6.5 months(1-47 months).AEs were reported in 9 patients,including 6 cases of dermatitis and 3 cases of heat sensation.In terms of severity,5 were categorized as class-1 AE,3 as class-2 AE,and 1 as class-3 AE.The median follow-up duration was 14 months(range:7-51 months),with 8 patients followed for more than 12 months.At the last follow-up,10 patients were alive,and 2 deceased at 15 and 33 months postoperatively.Eight patients experienced disease progression with a PFS ranging from 2 to 26 months.Four patients had a PFS ≥12 months.Conclusion In both newly-diagnosed and recurrent GBMs TTFields therapy causes mild to moderate localized AEs while it could potentially contribute to enhanced patient survival.
NETL
NSTL
万方数据
